-

07:23:09 AM

Latest TWST Stock Market News

TWST - Twist Bioscience Corp

09/20/21 8:00 AM

Nasdaq, NYSE : ILMN, SQZ, TWST

Illumina Ventures Closes $325 Million Fund

Illumina Ventures, an independently-managed, healthcare-focused venture firm, announced today the closing of its second investment fund with total commitments of $325 million, bringing its total capital under management to $560 million. Since its launch in 2016, Illumina Ventures has made investments in 25 companies, including Actym Therapeutics,...

RHEA-AI

very positive

09/14/21 8:00 AM

Nasdaq : TWST

covid-19

Twist Bioscience Continues Commitment to Deliver Synthetic RNA Controls, now to Fight Delta Plus Variants of COVID-19

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has started shipping its synthetic RNA reference controls for the SARS-CoV-2 AY.1 and AY.2, more commonly known as Delta Plus. “We continue to update our synthetic controls for the...

RHEA-AI

neutral

09/13/21 8:00 AM

Nasdaq : ACET, TWST

Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Adicet Bio, Inc., a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other...

RHEA-AI

positive

09/09/21 9:56 AM

Nasdaq : TWST

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a broad-based research collaboration with Boehringer Ingelheim International GmbH to use Twist’ s proprietary antibody libraries to...

RHEA-AI

positive

09/09/21 8:00 AM

Nasdaq : TWST

Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a broad-based research collaboration with Boehringer Ingelheim International GmbH to use Twist’ s proprietary antibody libraries to...

RHEA-AI

neutral

09/08/21 8:00 AM

Nasdaq : TWST

conferences

Twist Bioscience to Present at Baird 2021 Global Healthcare Conference

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present virtually at the Baird 2021 Global Healthcare Conference on...

RHEA-AI

neutral

08/10/21 8:00 AM

Nasdaq : TWST

conferences

Twist Bioscience to Present at UBS Genomics 2.0 and Medtech Innovations Summit

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Jim Thorburn, CFO of Twist Bioscience, and Patrick Finn, chief commercial officer, will host a fireside chat at

RHEA-AI

neutral

08/06/21 7:35 AM

Nasdaq : TWST

earnings

Twist Bioscience Reports Third Quarter Fiscal 2021 Financial Results

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2021 ended June 30, 2021.“It is an exciting

RHEA-AI

neutral

08/06/21 7:30 AM

Nasdaq : TWST

management

Twist Bioscience Appoints Drug Discovery Leader Melissa Starovasnik, Ph.D., to Board of Directors

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it appointed Melissa Starovasnik, Ph.D. to its board of directors. Dr. Starovasnik most recently served as Senior

RHEA-AI

very positive

07/26/21 8:00 AM

Nasdaq : TWST

Twist Bioscience Incorporates MOLCURE AI Technology to Augment Therapeutic Antibody Discovery

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and MOLCURE Inc., today announced they generated potent, binding antibodies to an undisclosed oncology target for Twist’s internal

RHEA-AI

very positive

1 2 3 4 5 6 7 Next

TWST Data:

IndustryResearch and Development in Biotechnology
Websitewww.twistbioscience.com
CeoEmily Leproust
Security nameTwist Bioscience Corp
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code2836
Employees525
Tags
- Health Technology
- Biotechnology
Address681 Gateway Blvd.
StateCalifornia
CitySouth San Francisco
Zip94080
CountryUS
Phone18007190671

TWST Description:

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by 'writing' DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.